European parliamentarian: ‘Who is liable if an AI-based diagnosis is incorrect?’

Emerging technologies like AI and robotics have vast potential to improve healthcare. Few question this. What remains unclear is how meaningful the advances will be to healthcare providers and, more to the point, the patients they serve.

Given the uncertainty, policymakers must step up their efforts to steer technology developers in the right direction, beginning with steps to assure data privacy and security.

Tiemo Wölken, a German politician who serves on the European parliament’s legal affairs committee, makes the case and outlines a way forward in an opinion piece published Sept. 13 in The Parliament.

Wölken asks: Who is liable if an AI-based diagnosis is incorrect? Who is held accountable if a robot-assisted surgery goes wrong? Is it the doctor, the manufacturer or the patient agreeing to the treatment?

“As a lawyer, I believe it is important to point out that the legal liability for damage is a central issue in the health sector where the use of AI is concerned,” he writes. “Furthermore, AI-based systems need to be neutral and fair in order to ensure a non-biased outcome. … It is [policymakers’] responsibility to establish a framework that fosters trust, safeguards data privacy and sees to it that data ownership remains with the patient.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup